Business and Finance

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.

The companies will be financially committing $1 and $3 billion into their respective manufacturing facilities.

Dr. Reddy’s immuno-oncology drug for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma will be marketed under the brand name Zytorvi.

The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.

Why well-organized documentation is critical at every stage of the process.

The CDMO's California facility welcomes new production suites, a revamp of its development labs, and more.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, details the types of regulatory pressures and factors surrounding rising R&D costs that will affect the pharmaceutical industry.

The 50,000 square-foot plant is expected to augment the compounding and fulfillment experience for telehealth companies.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jonathan Colehower, managing director, global operations & supply chain practice at UST, describes how events such as the East and Gulf Coast port strikes have brought to light the differences between branded and generic pharmaceuticals.

Tips for pharmacies with the reimbursement blues.

Digital transformation initiatives are often complex endeavors that can significantly impact the way organizations operate.

Albert Thigpen, co-founder, Talentwise Consulting, shares how today’s consumer is empowered to make their own decisions as it relates to consumer choices in general, while outlining how the concept can be applicable to the healthcare and pharma industry.

Albert Thigpen, co-founder, Talentwise Consulting, explains how the specialty pharmacy sector has evolved over the years.

Are SDOHs associated with Medicare, Medicaid, and private insurer spending?

Albert Thigpen, co-founder, Talentwise Consulting, explains how to use these tactics in order to anticipate the future US healthcare policy environment.

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.

The offering will become available in 49 states by next year.

A panel dives into the current and future outlook of healthcare policies.

Session dives into how healthcare policy implementation impacts stakeholders long-term.

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena.

The conference’s opening keynote sets the scene for 2025 and the years to come.

The company’s annual edition reveals the latest numbers in the sector, including a rise in average employer-sponsored health insurance premiums for single and family coverage of 24% and 28% respectively.

A deep dive into the future of patient service programs and the value of transparency throughout the process.

How can buyers maximize the value of their acquisitions?